Cullgen is a biopharmaceutical company that has developed protein degradation technology that utilizes the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Our technology, which we call uSMITE™ (ubiquitin-mediated, small molecule-induced target elimination) has the potential to address a broad range of intracellular disease targets, including those representing the up to 80% of proteins that cannot be addressed by existing small molecule therapies, commonly referred to as undruggable targets. In addition to using our uSMITE™ platform to build our own pipeline of protein degradation product candidates, we are also developing a portfolio of novel E3 ligands. You can learn more information about Cullgen on our website: www.Cullgen.com
Location: United States, California, San Diego
Employees: 51-200
Total raised: $121M
Founded date: 2018
Investors 2
| Date | Name | Website |
| 06.01.2021 | 3E Biovent... | 3ebiovc.co... |
| - | Octagon Ca... | octagoninv... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 09.05.2023 | Series C | $40M | - |
| 25.02.2021 | Series B | $50M | - |
| 10.04.2019 | Series A | $16M | - |
| 01.03.2018 | Seed | $15M | - |
Mentions in press and media 17
| Date | Title | Description |
| 09.05.2023 | US-headquartered biotech firm Cullgen snaps $40m in Series C round | Biotech firm Cullgen, a clinical-stage biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches, has bagged a total of $40 m... |
| 08.05.2023 | Cullgen Raises $40M in Financing | Cullgen, Inc., a San Diego, CA and Shangai, China-based biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, raised $40m in funding. A $35m series... |
| 08.05.2023 | Cullgen closes $40M round to support their tech platform and internal pipeline of targeted protein degraders | - |
| 25.06.2021 | Roth Capital Partners to Host a Virtual Healthcare Private Company Forum on June 28, 2021 | NEWPORT BEACH, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Roth Capital Partners (“Roth”), www.roth.com, is set to virtually present the Roth Virtual Healthcare Private Company Forum on June 28th, 2021. This event will con... |
| 25.02.2021 | CULLGEN CLOSES $50 MILLION SERIES B INVESTMENT TO ADVANCE TARGETED PROTEIN DEGRADERS AND NOVEL E3 LIGANDS PLATFORM | - |
| 25.02.2021 | Cullgen Completes $50M Series B Financing | SAN DIEGO, CA, Cullgen today announced that it has closed a $50 million Series B financing (assuming exercise of warrant). >> Click here for more funding data on Cullgen >> To export Cullgen funding data to PDF and Excel, cl... |
| 25.02.2021 | Cullgen Closes $50 Million Series B Investment to Advance Targeted Protein Degraders and Novel E3 Ligands Platform | SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Feb 25, 2021-- Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today annou... |
| 25.02.2021 | Cullgen has raised $50M in a Series B to support the development of the company's technology platform and internal pipeline of targeted protein degraders | - |
| 14.04.2019 | Biotech Startup Cullgen Raises $16M Series A | Cullgen, a San Diego-based biotechnology company, raised $16 million in a series A funding round led by Sequoia Capital China and Highlight Capital. Cullgen, which has offices in Carmel Valley and Shanghai, is developing treatments for canc... |
| 11.04.2019 | Insurance Tech Startup Lemonade Raises $300 Million in Funding: Term Sheet for Thursday, April 11 | MAKING LEMONADE Softbank is doubling down on Lemonade. Paid Content You can't secure what you can't see From ExtraHop Here’s how Fortune described the startup in 2016: It pools insurance premiums from people who know and trust one another. ... |
Show more